InvestSMART

Osteopore Limited (ASX:OSX)

ALERT: Price-sensitive ASX Announcement for OSX
Current share price for OSX : $0.005 -0.001 (-16.67%)+
Announcement
Release
26 May 2026 8:59AM
Price at Release
$0.006
Full Release
download
Summary
Osteopore Limited, an Australian-Singaporean regenerative medicine company, has received approval from the Hainan Medical Products Administration (Hainan FDA) for the clinical use of its orthopaedic custom devices. This approval enables the company to market and use its devices at Shanghai Ruijin Hospital's Hainan branch, located in the Hainan Boao Lecheng International Medical Tourism Pilot Zone. The strategic location benefits from preferential policies allowing innovative medical practices before full mainland approval. The Hainan FDA approval is seen as both a commercial launchpad and a pathway to broader market access in China, where the orthopaedic market is expected to grow significantly. The first surgery with these devices is scheduled for June 2026.
Key Points
  • Osteopore Limited has secured approval from Hainan FDA for its orthopaedic devices.
  • The approval allows clinical use at the Hainan branch of Shanghai Ruijin Hospital.
  • Hainan Boao Lecheng International Medical Tourism Pilot Zone is China's special medical zone.
  • The China orthopaedic market is significant, with a projected growth to USD 4.5 billion by 2035.
  • Hainan FDA approval serves as a launchpad and regulatory springboard for China-wide access.
  • First patient surgery is scheduled for June 2026 at the Hainan hospital.
IMPORTANT NOTE: This information is autogenerated and has not been reviewed for accuracy or completeness. You should refer to the full announcement here for further information.